|
1
|
Sauter JL, Kadota K, Bueno R, Ladanyi M, Dacic S, Nowak AK, Gill RR, Schmitt F and Husain AN: Diffuse pleural mesothelioma. WHO Classification of Tumours: thoracic Tumours. IARC Press; Lyon: pp. 204–219. 2021
|
|
2
|
Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Sallé F, et al: Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: A multi-institutional study. Mod Pathol. 31:598–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chapel DB, Schulte JJ, Husain AN and Krausz T: Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res. 9 (Suppl 1):S3–S27. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kinoshita Y, Hamasaki M, Matsumoto S, Yoshimura M, Sato A, Tsujimura T, Kamei T, Kawahara K and Nabeshima K: Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma. Pathol Int. 70:671–679. 2020.PubMed/NCBI
|
|
5
|
Illei PB, Rusch VW, Zakowski MF and Ladanyi M: Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 9:2108–2113. 2003.PubMed/NCBI
|
|
6
|
Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM and Churg A: BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 39:977–982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Iwasaki A and Nabeshima K: Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. Lung Cancer. 130:187–193. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hamasaki M, Matsumoto S, Abe S, Hamatake D, Kamei T, Hiroshima K, Kawahara K, Sato A, Tsujimura T, Nakatani Y, et al: Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma. Lung Cancer. 99:155–161. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Savola S, Nardi F, Scotlandi K, Picci P and Knuutila S: Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogenet Genome Res. 119:21–26. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Usvasalo A, Savola S, Räty R, Vettenranta K, Harila-Saari A, Koistinen P, Savolainen ER, Elonen E, Saarinen-Pihkala UM and Knuutila S: CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: An array CGH study. Leuk Res. 32:1228–1235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martinez Ciarpaglini C, Gonzalez J, Sanchez B, Agusti J, Navarro L, Nieto G and Monteagudo C: The amount of melanin influences p16 loss in spitzoid melanocytic lesions: Correlation with CDKN2A status by FISH and MLPA. Appl Immunohistochem Mol Morphol. 27:423–429. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsutsumi Y, Chinen Y, Sakamoto N, Nagoshi H, Nishida K, Kobayashi S, Yokokawa Y, Taki T, Sasaki N, Yamamoto-Sugitani M, et al: Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality. Leuk Lymphoma. 54:2760–2764. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mizuno Y, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Matsumura-Kimoto Y, Fujibayashi Y, Kuwahara-Ota S, Fujino T, Nishiyama D, Shimura Y, et al: A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma. Int J Hematol. 109:593–602. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, et al: Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer. 104:98–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sato A, Torii I, Tao LH, Song M, Kondo N, Yoshikawa Y, Hashimoto-Tamaoki T, Hasegawa S, Nakano T and Tsujimura T: Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma. Cancer Sci. 102:648–655. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ and Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54:5547–5551. 1994.PubMed/NCBI
|
